Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...
Uncover hidden gems in the stock market with the 'Undercovered Dozen' series featuring undervalued stocks with potential for ...
On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...
Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the ...
This has been an amazing year for stocks. From the end of 2023 through Nov. 12, the benchmark S&P 500 index climbed 25% ...
Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...
Syndax recently geared up for commercialization by inking a $350 million deal with Royalty Pharma. That cash influx will be ...
Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...
Nxera stands to benefit from the potential appreciation of its equity holding in Centessa and also from further milestone payments and royalty income tied to the successful development of ORX750. Matt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback